Cost-effective solutions
for large chemical space exploration

Accelerate your drug discovery process and reduce costs

Besides the upfront investments in infrastructure, one of the major barriers to access and exploit ultra High Throughput Screening (uHTS) of large compound libraries for academic centres, start-ups, and biotech companies active in drug discovery research, is the inherent high cost of reagents and consumables. Miniaturisation is key to reduce time and costs during the screening campaigns of large compound libraries and receive your high-quality hit lists. Whether you already have an assay in place in 96- or 384-well plate format or you want us to do the assay development for your target from scratch, we can miniaturise them to 1536-well format for screening purposes.

During assay development, optimization and miniaturisation, several experiments are performed for each project to check for appropriate assay component concentrations, stability of reagents and their minimal required concentrations or volumes, kinetics (such as incubation time, temperature, Km/Kd determination), assay linearity, EC50/IC50 of reference compounds, inter-/intraplate variation, DMSO tolerance, optimal final reagent concentrations and volume per well required, plate effects as well as robustness of the assay using reagents, chemicals, and microtiter plates from different vendors. For this, several factors beyond and above assay robustness and window were taken into consideration, such as the choice of appropriate protein (state) and biochemically sound assay composition including concentrations of assay components, types of salts, pH, reducing agents, detergents, primary assay pitfalls, and so forth.